KIRKLAND, QC, May 9, 2013 /CNW Telbec/ - Merck announced today that the
company has been awarded a significant portion of the UNICEF human
papillomavirus (HPV) vaccine tender, and will provide sustained supply
of GARDASIL® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant
Vaccine] to GAVI-eligible countries. This agreement follows the GAVI
Alliance's earlier announcement that HPV vaccines would be included in
its portfolio for the first time. GAVI is expected to support the
introduction of HPV vaccination in 28 countries by the end of 2017.
GAVI Alliance is a public-private partnership focused on saving
children's lives and protecting people's health by increasing access to
immunization in poor countries.
Through this initial tender award, Merck expects to supply approximately
2.4 million doses of GARDASIL to GAVI-eligible countries between 2013
to 2017 to help meet vaccine demand for countries already approved or
recommended for approval by GAVI for HPV vaccine demonstration projects
and national introductions. Additional awards by UNICEF are
anticipated as vaccine demand increases.
"It is essential that every young girl around the world have access to
HPV vaccines. Today's decision by UNICEF is an important step forward,"
said Julie L. Gerberding, M.D., president, Merck Vaccines. "This
partnership highlights Merck's commitment to working closely with GAVI
to ensure broad and sustained access to GARDASIL in the world's poorest
countries, where the burden of cervical cancer is greatest."
"A vast gap currently exists between girls in rich and poor countries.
With today's announcement, GAVI's programmes can begin to bridge that
gap so that girls can be protected against cervical cancer no matter
where they are born," said Dr. Seth Berkley, CEO of the GAVI Alliance.
"By 2020 we hope to reach more than 30 million girls in more than 40
countries. This is a transformational moment for the health of women
and girls across the world. We thank the manufacturers for working with
us to help make this happen."
Following a 2009 report, the World Health Organization recommended that
routine HPV vaccination be included in national immunization programs
to help prevent cervical cancer and other HPV-related diseases. It is
estimated that approximately 500,000 women develop cervical cancer
annually around the world, with about 85 percent of cases occurring in
developing countries. Cervical cancer is the third most common type of
cancer among women worldwide. High-risk HPV types 16 and 18 cause about
75 percent of cervical cancers, 70 percent of vaginal cancers, 40 to 50
percent of vulvar cancers and 80 percent of anal cancers.
Other Merck access efforts for GARDASIL in the developing world
Merck is pursuing a systematic and thoughtful approach to improve access
to GARDASIL in the developing world through four key pillars:
innovation, partnerships, pricing and implementation. Key efforts
In September 2012, Merck announced it will donate 460,000 doses of
GARDASIL over a two-year period to the Republic of Uganda to help the
Ministry of Health launch a HPV vaccination program in 12 districts in
the country. The program represents the first phase of Uganda's
national rollout plan for HPV vaccination.
In April 2011, the Government of Rwanda, Merck and QIAGEN launched a
comprehensive cervical cancer prevention program in Rwanda
incorporating both HPV vaccination and HPV testing, the first program
of its kind in Africa. In its initial year, an estimated 93 percent of
eligible girls 12 to 15 years of age in Rwanda were vaccinated with
three doses of GARDASIL.
In 2010 Merck partnered with the Royal Government of Bhutan and the
Australian Cervical Cancer Foundation to launch a six-year national
vaccination program with GARDASIL for appropriate girls and young women
between the ages of 12 and 18 in Bhutan. Merck provided GARDASIL to
the program partners at no cost in the first year and for the remaining
five years is providing it at an access price.
In 2009 Merck also announced a partnership with QIAGEN N.V. focused on
increasing access to HPV vaccination and HPV DNA testing in some of the
most resource-poor areas of the world. This initiative was the first
time a vaccine manufacturer and a molecular diagnostics company
collaborated to help address the burden of cervical cancer with a
Merck has also donated more than one million doses of GARDASIL
[Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant
Vaccine] through the GARDASIL Access Program, which was established in
2007 to help enable organizations and institutions in eligible lowest
income countries to gain operational experience designing and
implementing HPV vaccination projects.
For further information about GARDASIL, please consult the product
monograph available at www.merck.ca.
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our medicines, vaccines, biologic therapies, and consumer and
animal products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate
our commitment to increasing access to healthcare through far-reaching
policies, programs and partnerships. For more information about our
operations in Canada, visit www.merck.ca.
Merck Forward-Looking Statement
This news release includes "forward-looking statements" within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck's management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care
cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; Merck's ability
to accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
Merck's patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can
be found in Merck's 2012 Annual Report on Form 10-K and the company's
other filings with the Securities and Exchange Commission (SEC)
available at the SEC's Internet site (www.sec.gov).
GARDASIL® is a registered trademark of Merck & Co., Inc., Whitehouse Station,
SOURCE: MERCK CANADA INC.
For further information: